KALV
KalVista Pharmaceuticals, Inc.
NASDAQ · USHealthcareBiotechnology
$27.00+0.00%
Price as of Jun 12, 2026
KALV financials
KalVista Pharmaceuticals, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2025 | 2024 | 2023 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $73.6M | $0.00 | $0.00 | $0.00 |
| Cost of revenue | $6.1M | $0.00 | $86.2M | $0.00 |
| Gross profit | $67.5M | $0.00 | -$86.2M | $0.00 |
| Operating expenses | $239.4M | $188.0M | $54.3M | $110.9M |
| Operating income | -$171.8M | -$188.0M | -$140.4M | -$110.9M |
| Net income | -$164.3M | -$183.4M | -$126.6M | -$92.9M |
| EBITDA | -$150.6M | -$173.3M | -$134.3M | -$94.4M |
| Basic EPS | $-3.23 | $-3.69 | $-3.44 | $-3.33 |
| Diluted EPS | $-3.23 | $-3.69 | $-3.44 | $-3.33 |
| Balance sheet | ||||
| Cash & equivalents | $229.3M | $98.6M | $31.8M | $56.2M |
| Total assets | $335.4M | $250.8M | $235.4M | $183.2M |
| Total liabilities | $338.1M | $155.4M | $28.8M | $22.2M |
| Stockholders’ equity | -$2.7M | $95.4M | $206.6M | $161.0M |
| Total debt | $151.6M | $6.3M | $7.3M | $8.2M |
| Net debt | -$77.8M | -$92.3M | -$24.5M | -$48.0M |
| Cash flow | ||||
| Operating cash flow | -$81.6M | -$152.9M | -$89.2M | -$75.3M |
| Capital expenditure | -$1.7M | -$434.0K | -$443.0K | -$1.2M |
| Free cash flow | -$83.3M | -$153.3M | -$89.7M | -$76.5M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |